ASF Funded Research leads to a collaboration for gene therapy to correct deficiency in UBE3A gene Asklepios BioPharmaceutical, Inc. (AskBio), a leading clinical-stage adeno-associated virus (AAV) gene therapy company, entered into a research collaboration and licensing agreement with the […]Read more
2020 ASF Walk
Join us in September.
Close to 50 locations around the US. Find the one nearest you.
Since her diagnosis, we have relied on the Angelman Syndrome Foundation as a source of information and support.
The Angelman Syndrome Clinic at MGH is a blessing for my adult child. Now we have somebody who really understand our needs.
Amazing things have happened because of the ASF-funded LGIT study from Boston’s MassGeneral Hospital. It was the beginning of a new era for treatments for our children with AS.
IN THE NEWS
Latest press releases, articles and announcements
Coronavirus Disease 2019 (COVID-19) Questions and Answers (FAQs) Due to quickly evolving information, recommendations may be subject to change and will be updated as needed. The 15q Clinical Research Network has prepared these FAQs to address concerns from the Angelman/Dup15q […]Read more
A new network platform, Linking Angelman and Dup15q Data for Expanded Research (LADDER), will offer caregivers access to information about a larger population of patients living with Angelman or Dup15 syndromes to better inform their decisions regarding treatments and interventions. […]Read more
Angelman Syndrome Foundation and Dup15q Alliance Announce Development of the International Clinical Research Network in efforts to help those living with 15q syndromes. Thousands of families affected by Angelman syndrome (AS) and dup15q syndrome will soon have greater access to […]Read more